PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin
in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day
0) to the end of the 12-week double-blind treatment period.